Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

Authors:
A Avogaro
A Avogaro
University of Padova
Italy

Acta Diabetol 2019 Apr 16. Epub 2019 Apr 16.

Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy.

Aims: Patients with type 2 diabetes (T2D) have an increased risk of cardiovascular disease. Recent cardiovascular outcome trials (CVOTs) with liraglutide, semaglutide, and albiglutide have shown significant reduction in major adverse cardiovascular events. Conversely, the CVOT with exenatide long-acting release (ELAR) confirmed cardiovascular safety of the drug, but did not reached superiority versus placebo. Herein, we systematically evaluated the effect of ELAR versus placebo or active comparators on cardiovascular events and mortality in patients with T2D.

Methods: We screened the literature for randomized controlled trials reporting cardiovascular events and deaths in patients receiving ELAR versus those receiving placebo or any other glucose-lowering medications. Event rates were pooled and compared using the random-effects model.

Result: We retrieved 16 trials comparing the occurrence of cardiovascular events and mortality in patients treated with ELAR versus placebo or active comparators. The pooled rate ratio for cardiovascular events was similar in the two groups (0.99; 95% CI 0.92-1.06). The rate ratio for all-cause mortality was significantly lower in exenatide group than in comparators (0.87; 95% CI 0.77-0.97). When results of the EXSCEL trial were omitted, the pooled rate ratio for cardiovascular events and mortality was 0.80 (95% CI 0.40-1.63) and 0.75 (95% CI 0.30-1.84), respectively.

Conclusions: Treatment with ELAR does not increase the risk of cardiovascular events and may reduce all-cause mortality.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00592-019-01347-0DOI Listing
April 2019

Publication Analysis

Top Keywords

cardiovascular events
32
events mortality
16
mortality patients
12
rate ratio
12
elar versus
12
versus placebo
12
cardiovascular
11
ratio cardiovascular
8
type diabetes
8
pooled rate
8
controlled trials
8
randomized controlled
8
risk cardiovascular
8
placebo active
8
all-cause mortality
8
patients type
8
long-acting release
8
events
8
exenatide long-acting
8
active comparators
8

References

(Supplied by CrossRef)
Article in Lancet
N Sarwar et al.
Lancet 2010
Article in N Engl J Med.
SR Kondapally Seshasai et al.
N Engl J Med. 2011
Article in Lancet Diabetes Endocrinol
S Zoungas et al.
Lancet Diabetes Endocrinol 2017
Article in N Engl J Med
RR Holman et al.
N Engl J Med 2008
Article in N Engl J Med
M Uni- et al.
N Engl J Med 2011
Article in N Engl J Med
SE Nissen et al.
N Engl J Med 2007
Article in Cardiovasc Diabetol
JR Petrie et al.
Cardiovasc Diabetol 2013
Article in N Engl J Med
MA Pfeffer et al.
N Engl J Med 2015
Article in Ann Clin Biochem
B Jones et al.
Ann Clin Biochem 2016
Article in N Engl J Med
SP Marso et al.
N Engl J Med 2016
Article in Lancet
AF Hernandez et al.
Lancet 2018

Similar Publications